HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wan-Hong Zhao Selected Research

Chimeric Antigen Receptors

4/2024Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
12/2022Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.
12/2018A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wan-Hong Zhao Research Topics

Disease

5Multiple Myeloma
04/2024 - 04/2006
4Neoplasms (Cancer)
12/2018 - 04/2006
3Acute Monocytic Leukemia (Acute Monoblastic Leukemia)
10/2019 - 02/2018
2Thrombocytopenia (Thrombopenia)
12/2018 - 04/2015
2Lymphoma (Lymphomas)
08/2016 - 04/2014
2Leukemia
01/2016 - 06/2007
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2016 - 04/2015
2Non-Hodgkin Lymphoma (Lymphosarcoma)
12/2015 - 01/2014
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/2015 - 03/2008
1Disease Progression
12/2022
1Obesity
10/2022
1Leukopenia
12/2018
1Aplastic Anemia (Anemia, Hypoplastic)
03/2016
1Anemia
04/2015
1Hemorrhage
04/2015
1Infections
04/2015
1Neutropenia
04/2014
1Necrosis
10/2007
1Refractory Anemia
10/2005
1Cytopenia
10/2005
1Myeloid Leukemia (Leukemia, Myelocytic)
08/2003

Drug/Important Bio-Agent (IBA)

4Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2016 - 03/2008
3Chimeric Antigen ReceptorsIBA
04/2024 - 12/2018
3AntigensIBA
06/2019 - 04/2006
3Cytarabine (Cytosar-U)FDA LinkGeneric
01/2016 - 03/2008
2B-Cell Maturation AntigenIBA
04/2024 - 12/2018
2Proteins (Proteins, Gene)FDA Link
10/2022 - 04/2006
2Therapeutic UsesIBA
03/2016 - 06/2007
2HomoharringtonineIBA
01/2016 - 03/2008
2Complementary DNA (cDNA)IBA
04/2006 - 08/2003
1bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA
04/2024
1Trans Fatty AcidsIBA
10/2022
1Transcription Factors (Transcription Factor)IBA
10/2019
1EpitopesIBA
12/2018
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
12/2018
1Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
03/2016
1Thalidomide (Thalomid)FDA Link
10/2015
1nartograstimIBA
04/2014
1Interleukin-8 (Interleukin 8)IBA
04/2014
1Interleukin-10 (Interleukin 10)IBA
01/2014
1ODN2006IBA
10/2007
1Vaccine AdjuvantsIBA
10/2007
1CPG-oligonucleotideIBA
10/2007
1VaccinesIBA
10/2007
1CpG ODN 1826IBA
10/2007
1Tryptophan (L-Tryptophan)FDA Link
06/2007
1Translationally-Controlled 1 Tumor ProteinIBA
04/2006
1Hemoglobins (Hemoglobin)IBA
10/2005
1Tretinoin (Retinoic Acid)FDA LinkGeneric
10/2005
1AndrogensIBA
10/2005
1RNA (Ribonucleic Acid)IBA
08/2003
1Messenger RNA (mRNA)IBA
08/2003

Therapy/Procedure

6Drug Therapy (Chemotherapy)
08/2016 - 03/2008
2Aftercare (After-Treatment)
04/2024 - 10/2015
1Therapeutics
12/2018
1Combination Drug Therapy (Combination Chemotherapy)
03/2008